Volume pricing
| Quantity | Per vial | Save |
|---|---|---|
| 1–4 | 206.00 USDT | — |
| 5–9 | 195.50 USDT | 5% |
| 10–24 | 181.00 USDT | 12% |
| 25–49 | 169.00 USDT | 18% |
| 50+ | 154.50 USDT | 25% |
Survodutide
For Research Use Only · Not for Human Consumption
Weight lossMetabolic
Survodutide is a dual agonist targeting the glucagon and GLP-1 receptors, investigated in preclinical settings for its effects on hepatic lipid handling, energy expenditure and incretin signalling crosstalk. Supplied as lyophilized powder at ≥98% HPLC purity. For Research Use Only. Not for Human Consumption. Not a drug, food, or cosmetic.
Potential benefits — preclinical research
- •Dual GLP-1 / glucagon receptor agonist — investigational triple-energy expenditure approach.
- •Up to ~19% body-weight reduction in Phase 2 obesity trials.
- •Significant reduction in liver fat (~80%) in NASH research.
Findings reported in published in-vitro / animal studies. Not therapeutic claims — for research use only.
Certificate of Analysis
Coming soon⏱Ships within 15 days — made to order
206.00 USDTper vial
≈ €189.52